HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 364 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $352,624 | -6.2% | 9,231 | -11.4% | 0.21% | -4.0% |
| Q2 2023 | $375,922 | +87.1% | 10,422 | +98.1% | 0.22% | +100.9% |
| Q1 2023 | $200,956 | -31.7% | 5,262 | +1.8% | 0.11% | -27.9% |
| Q4 2022 | $294,173 | +37.5% | 5,170 | -4.3% | 0.15% | +81.2% |
| Q3 2022 | $214,000 | -8.5% | 5,400 | +1.4% | 0.08% | -2.3% |
| Q2 2022 | $234,000 | -45.3% | 5,324 | -50.4% | 0.09% | -54.7% |
| Q1 2022 | $428,000 | -0.9% | 10,738 | 0.0% | 0.19% | +17.8% |
| Q4 2021 | $432,000 | +0.7% | 10,738 | +1.8% | 0.16% | -13.8% |
| Q3 2021 | $429,000 | -18.0% | 10,551 | -8.4% | 0.19% | -12.1% |
| Q2 2021 | $523,000 | -16.1% | 11,515 | -23.0% | 0.22% | -18.3% |
| Q1 2021 | $623,000 | +0.3% | 14,954 | +2.8% | 0.26% | +1.9% |
| Q4 2020 | $621,000 | -7.7% | 14,543 | -43.2% | 0.26% | -26.9% |
| Q3 2020 | $673,000 | +7.0% | 25,612 | +9.2% | 0.35% | +18.5% |
| Q2 2020 | $629,000 | +12.7% | 23,455 | -24.3% | 0.30% | +29.6% |
| Q1 2020 | $558,000 | -6.4% | 30,996 | -7.8% | 0.23% | +137.1% |
| Q4 2019 | $596,000 | -12.7% | 33,612 | -23.7% | 0.10% | -29.7% |
| Q3 2019 | $683,000 | -22.7% | 44,046 | -14.4% | 0.14% | -25.8% |
| Q2 2019 | $884,000 | +8.1% | 51,461 | +1.2% | 0.19% | -89.3% |
| Q1 2019 | $818,000 | +40.1% | 50,835 | +27.3% | 1.74% | +1640.0% |
| Q4 2018 | $584,000 | -22.0% | 39,935 | -3.1% | 0.10% | +29.9% |
| Q3 2018 | $749,000 | +15.6% | 41,199 | +7.2% | 0.08% | -86.6% |
| Q2 2018 | $648,000 | -27.8% | 38,423 | -16.1% | 0.57% | -26.4% |
| Q1 2018 | $898,000 | -8.5% | 45,820 | -5.3% | 0.78% | -36.7% |
| Q4 2017 | $981,000 | -27.9% | 48,401 | -38.2% | 1.23% | +572.7% |
| Q3 2017 | $1,361,000 | +35.6% | 78,354 | 0.0% | 0.18% | +22.0% |
| Q2 2017 | $1,004,000 | -17.8% | 78,354 | -16.9% | 0.15% | -31.2% |
| Q1 2017 | $1,222,000 | +45.1% | 94,299 | +10.6% | 0.22% | -13.5% |
| Q4 2016 | $842,000 | -0.6% | 85,231 | +21.6% | 0.25% | -38.5% |
| Q3 2016 | $847,000 | +60.1% | 70,108 | +14.4% | 0.41% | +4.3% |
| Q2 2016 | $529,000 | +52.0% | 61,274 | +67.0% | 0.39% | -18.0% |
| Q1 2016 | $348,000 | – | 36,695 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |